Radiotherapy for ductal carcinoma in situ.
OBJECTIVE
The introduction of breast screening mammography has led to an increase in the diagnosis of ductal carcinoma in situ (DCIS). Mastectomy gives high rates of local control. However, most cases are suitable for local excision. The aim of this article is to review the role of radiotherapy in the treatment of DCIS after breast conserving surgery.


METHODS
A review of the literature relating to radiotherapy and DCIS RESULTS: The published trials show that adjuvant radiotherapy after breast conserving surgery halves the ipsilateral recurrence rates of DCIS and invasive cancer. No subgroups have been reliably identified that do not benefit from adjuvant radiotherapy. Risk factors for recurrence are discussed.


CONCLUSIONS
All patients with DCIS have potential benefit to gain from adjuvant radiotherapy. However, radiotherapy also has adverse effects and represents over-treatment from many women. Support should be given to current trials which are assessing endocrine treatment of DCIS, and whether radiotherapy can reasonably be omitted in lower risk disease.
Adlard
J W
JW
Yorkshire Regional Centre for Cancer Treatment, Cookridge Hospital, Leeds, UK. jwa@doctors.org.uk
Bundredt
N J
NJ
D001943:Breast Neoplasms / Q000532:radiotherapy* / Q000601:surgery; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000532:radiotherapy* / Q000601:surgery; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008408:Mastectomy; D018579:Patient Selection; D018714:Radiotherapy, Adjuvant; D016387:Women's Health